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ABSTRACT 
Lead (Pb) is one of the most likely toxicants that could be potentially a risk factor in the development of Multiple 
Sclerosis (MS) through changes in the immune system. The purpose of the study was to describe the clinical features 
of MS in general and  for sub-groups stratified for gender, age, residence, disease duration, disability degree, clinical 
diagnosis in Isfahan, Iran and also, to elucidate the relationship between the blood Pb level and the development of 
MS.  Blood samples of 48 patients (20 to 57 years) were selected from the department of neurology of the Kashani 
hospital in Isfahan, Iran and were analyzed for Pb using anodic stripping voltammetry (ASV). The clinical and 
demographic characteristics in our study were similar to those in other reports. The blood Pb level in 70.83% of the 
total population was <20 μg/l. No statistically significant difference was observed between the Pb level and some 
patient characteristics. These findings did not support the assumption that Pb could be a pathogenetic factor in MS. 
However, the exposure to a large amount of Pb can increase the risk of developing MS. Obviously; more 
investigation is needed to investigate the contribution of Pb to the development of MS. 
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LIST OF ABBREVIATIONS 
- Multiple sclerosis (MS) 
- Lead (Pb) 
- Anodic Stripping Voltammetry (ASV) 
- Relapsing–remitting MS (RRMS) 
- Progressive–relapsing MS (PRMS) 
- Secondary-progressive MS(SPMS) 
- Primary-progressive MS (PPMS) 
- Clinically Isolated Syndrome (CIS) 
- Motor neuron disease (MND) 
- Expanded Disability Status Scale (EDSS) 
- Electrothermal atomic absorption spectrometry(E. A. A. S)  
- Zeeman modulated atomic absorption spectrometry (Z.M.A.A.S.) 
- Neutron activation analysis (N.A.A.) 
- Atomic absorption spectrometry (A.A.S) 
- Inductively coupled plasma mass spectrometry (ICP-MS) 
- Graphite-furnace atomic absorption spectrometry (GFAAS) 
 
INTRODUCTION 
Multiple sclerosis (MS) is an acquired inflammatory 
and neurodegenerative immuno-mediated disorder of 
the central nervous system, characterized by 
inflammation, demyelination and primary or 
secondary axonal degeneration [1]. It clinically 
manifests itself with signs of multiple neurological 
dysfunctions (e.g. visual and sensory disturbances, 
bilateral Babinski signs, limb weakness, gait 
problems and bladder and bowel symptoms) followed 
by recovery or growing disability because of 
irreversible functional disability over time [1,3].  
The categorization of the clinical course of MS has 
been reported to be(i) relapsing–remitting MS 
(RRMS), (ii) progressive–relapsing MS (PRMS), (iii) 
secondary-progressive MS(SPMS), (iv)primary-
progressive MS (PPMS). Patients usually experience 
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a first neurologic event suggestive of MS which is 
known as Clinically Isolated Syndrome (CIS) [1,4].  
The etiology of MS is still unknown, though it is 
likely to be caused by the interaction of changes in a 
range of social and environmental factors with 
underlying genetic differences [5,6]. Some progress 
has been made in trying to understand the role of 
heavy metals, principally lead (Pb), in 
neurodegenerative diseases such as multiple 
sclerosis, amylotrophic sclerosis, and Alzheimer’s [7-
9]. 
Lead is a non-essential and toxic metal that is 
naturally present in the environment.  Lead enters the 
environment during production (including mining 
and smelting), use (batteries, pigments, ceramics, 
plastics), recycling, disposal of Pb compounds, 
combustion of fossil fuels, the use of mineral 
fertilizers, sewage sludge application, etc. [10]. 
There is no direct evidence showing that lead alters 
the immune system in a way that can increase the risk 
of MS. Some researchers have found that lead may 
stimulate the immune response by enhancing the 
immunogenicity of molecules of neural proteins [9]. 
Also, Pb, as responsible for the formation of 
antibodies against myelin proteins, is suspected to 
play a role in the pathogenesis of nervous system 
diseases such as MS [11]. However, the possible 
relation between exposure to lead and the 
development of neurodegenerative diseases has not 
been well studied [7].  
Isfahan Province in Iran is now globally well known 
for its high prevalence of Multiple Sclerosis. Isfahan 
is recognized as one of the most high-risk regions for 
MS in Asia and Oceania [12]. The study by Isfahan 
MS society (IMSS) in reported a prevalence of 
73.3/100,000 and an incidence rate of 9.1/100,000 in 
2010 and also, an incidence rate of 9.22/100,000 in 
2011 [12]. Based on the final report of IMSS, the 
overall age-adjusted prevalence rate was increased to 
85.8/100,000 in 2014 [13], while the global median 
prevalence was increased from 30 (in 2008) to 33 per 
100,000 (in 2013) [5]. However, the prevalence rate 
of MS in our province is still increasing, making the 
prevention and control this disease one of the most 
growing concerns. 
Therefore, our purpose was to study the clinical 
features of MS for the whole population and for sub-
groups stratified for gender, age, residence, disease 
duration, disability degree, and clinical diagnosis in 
Isfahan, Iran. Also, this study was done to elucidate 
the role of the lead in the pathogenesis of MS for 
each stratification variable. In addition, we tested 
whether there were significant differences between 
the sub-samples and if there was a significant 
correlation between the variable and the metal level. 
National and international comparisons of Pb 
concentration in blood and in the air and soil 
environments were also reported.  
 
MATERIALS AND METHODS  
Isfahan is a large province covering an area of 
107,027 km2 in the central part of Iran. The climate 
is dry and temperate with the average temperature of 
5.7°C in winter and 27.2°C in summer. The annual 
rainfall is 122.7mm too. Total population is 
4,165,319 , 51.3% male and 48.7%  female; 84.9% 
live in the urban areas and 15.1% in rural districts 
[14].  
Study population and sampling 
At first, this study was carried out on 54 subjects with 
a new or already known diagnosis of definite, 
probable or possible MS. These patients, who had 
referred to the department of neurology at Kashani 
Hospital in Isfahan, Iran, participated in the study 
during two weeks of sampling in August 2013. From 
this population, 48 subjects were living inside the 
province and others (a few subjects) were from the 
surrounding Provinces and therefore, were excluded. 
We pursued a sample size with patients that had 
experienced different stages of this disease. All 
individuals were asked to fill a questionnaire in order 
to have information on the variables that could 
influence the blood Pb concentration. Based on 
similar studies  investigating the effect of heavy 
metals on human health and the  development of 
diseases such as the disorders of the central nervous 
system [6, 15-18], we chose such criteria as age 
groups to study exposure duration with different 
pollution sources in the life;  among other criteria, 
residence was noted to know the environment near 
the residence; disease duration was considered to 
check the changes of the blood lead level during the 
disease; disability degree  was checked to observe the 
effect of blood lead level of on disability; and finally, 
clinical diagnosis was conducted  to examine the 
effect of blood lead level on disease type. Disability 
was assessed by an expanded disability status scale 
(EDSS). EDSS had steps from 0 (normal) to 10 
(death due to MS). EDSS steps 1.0 to 4.5 refer to 
patients who are fully ambulatory. EDSS steps 5.0 to 
9.5 are defined by the impairment to ambulation [19]. 
Fortunately, the selected sample size had a desirable 
variety of criteria, such as gender (16 males and 32 
females), age (20 to 57 years), residence status (13 
subjects in rural areas and 35 in urban areas), disease 
duration (<20 days to 12 years), disability degree 
(ranged from 2 to 6) and clinical diagnosis (RRMS, 
SPMS and CIS), that could help us to find whether 
these parameters could influence the changes of the 
blood lead level.  
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Their blood was considered as an index of 
biologically heavy metals in the body, reflecting the 
environmental exposure of a population; hence, it 
was analyzed for heavy metal of Pb as a significant 
factor for individual health. 
Exclusion criteria were: cardiological, respiratory, 
kidney or liver disease, as well as intestinal 
absorption abnormalities, infections, assumption of 
thyroid hormones, intake of vitamin or mineral 
supplements, vegetarian dietary, and artificial 
metallic bodies. Also, some variables such as height, 
weight, marital status, dietary, education, length of 
stay in the area, smoking habits and occupation were 
not considered.   
Apparatus and reagents 
All electrochemical measurements of lead were 
performed with Metrohm (Model 797 VA 
computrace) equipped with static mercury dropping 
electrode. The three electrode system consisted of a 
working hanging mercury dropping electrode 
(HMDE), a platinum auxiliary electrode and an 
Ag/AgCl saturated with KCl as the reference 
electrode. pH values were measured with a Metrohm 
(Model 827 pH-lab) pH meter equipped with a 
combined glass electrode (Corning, Model 
6.0228.010). All the reagents used were of Analytical 
grade. All chemicals, being of analytical reagent 
grade, were purchased from Merck (Darmstadt, 
Germany) unless otherwise stated. Deionized water 
of resistivity higher than 18.0 mΩ at 25 ºC was used 
throughout. Acetate buffer 4.6  ±0.2 contained 14.2 
ml of acetic Acid plus 55.9g of KCl and 25 mL of 
NaOH 30% in to the 500 ml deionized water. A stock 
solution of 1000 ppm of lead was prepared by 
dissolving the salts of metal nitrates in distilled 
deionized water. Solutions of low concentrations was 
prepared by serial dilutions with de-ionized double 
distilled water. 
Sample preparation 
Organic matter often interferes with voltammetric 
determinations and therefore, sample solutions 
usually have to be digested. Therefore, 
approximately, 2 ml blood samples were taken from 
each patient with special care by vein puncture using 
disposable syringes and needles and placed into 
heparinized pretreated clean polypropylene tubes. 
The samples were allowed to coagulate for 1 h and 
serum was then obtained by centrifugation at 5000 
rpm for 10 min. The samples (2 ml) were then 
digested with nitric acid and perchloric acid. So, 
digested samples were made up to 4 ml. Therefore, 
all organic matter in the blood samples was removed 
for voltammetric measurement. 
Voltammetric measurement  
The prepared standard method in DIN 38406 Part 16 
describes the determination Pb by voltammetric 
method. All voltammetric measurements were 
achieved according to this method. 0.5 ml of the 
digested sample was transferred into the 
voltammetric cell containing 10 ml of KCl-sodium 
acetate buffer (pH 4.6). The solution in the cell was 
aerated for 5 minutes by purging pure nitrogen gas. 
Anodic stripping was performed in the differential 
pulse mode after selecting pre-concentration time of 
90s, a scan rate of 6 mV/s and pulse amplitude of 5 
mV. The concentration of lead in the samples was 
determined using the standard addition method. In 
the standard addition method, first, a voltammogram 
of Pb unknown concentration was recorded. Then, a 
small volume of a concentrated solution containing a 
known quantity of the Pb concentration was added to 
the sample. On the basis of the assumption that the 
response is linear, the increase in signal of this new 
solution could be used to estimate the amount of Pb 
unknown concentration in the original solution. 
Reagent blanks were taken along with each batch of 
samples and the metal concentration observed in 
these blank samples was subtracted from the 
corresponding batch of field samples. Blank samples 
always showed extremely low levels of trace metals. 
Statistical analysis 
The distribution of each population was checked 
through the Kolmogorov–Smirnov(K–S) test. Rates 
for various subgroups were compared by the X2 or 
Fisher exact test. The relationship between Pb 
concentration in blood samples and disease duration 
was statistically compared using the analysis of 
variance (ANOVA).A p-value of p< 0.05 was 
considered significant. All analyses were performed 
using SPSS version 9. 
 
RESULTS  
Demographic and Clinical Results  
The demographic and clinical results are given in 
Table 1. 
Generally Table 1 showed that the overall prevalence 
of MS among men and women was 16/48 (33.33%) 
and 32/48(66.67%), respectively. Women were 2 
times more likely to develop MS. The mean ±SE of 
the age of the patients was 33.73± 1.34 years, ranging 
from 20 to 57 years. The most common age group 
was that of 20-40years (79.17%), including 24 
females (75 %) and 14 males (87.5 %). The youngest 
female patient was 21, and the oldest was57, the 
youngest man was 20, and the oldest was48. Only 
6.25 % of cases were above 50. As regards the place 
of residence, subjects living in rural and urban areas 
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Table 1: Clinical Data on MS Patients, 16 men and 32 
women* 
Females Males All. Variables  
   Age of subjects (year) 
14(43.75) 7(43.75) 21(43.75) 20-30 
10(31.25) 7(43.75) 17(35.42) 30-40 
5(15.63) 2(12.50) 7(14.58) 40-50 
3(9.38) 0 3(6.25) >50 
   Residence 
7(21.88) 6(37.50) 13(27.08) Rural 





6(18.75) 2(12.50) 8(16.67) <20 
5(15.63) 3(18.75) 8(16.67) 30-60 
5(15.63) 1(6.25) 6(12.50) 365-730 
2(6.25) 6(37.50) 8(16.67) 1095-1460 
5(15.63) 2(12.50) 7(14.58) 1825-2555 
7(21.88) 0 7(14.58) 2920-3650 




Status Scale (EDSS)b 
9(28.13) 3(18.75) 12(25.00) 1 
15(46.88) 10(62.50) 25(52.08) 2 
7(21.88) 2(12.50) 9(18.75) 4 
1(3.13) 1(6.25) 2(4.17) 6 
   Clinical diagnosis 
18(56.25) 7(43.75) 25(52.08) RRMS 









23(71.88) 11(68.75) 34(70.83) <20 
3(9.38) 2(12.50) 5(10.42) 20-70 
1(3.13) 2(12.50) 3(6.25) 70-100 
5(15.63) 1(6.25) 6(12.50) 100-130 
-  Figures in parentheses indicate percentages 
*No significant differences were noted between males and females for 
all variables in chi-square test (P>0.05), except for Disease duration 
(P<0.05). 
 a  Significant difference between males and females.(Likelihood 
Ratio Chi-Square = 13.198, DF = 6,    P-Value = 0.040) 
 b Since the chi-squared test is generally reckoned to be unreliable if 
any of the expected frequencies are below 5,  merging some of 
the smaller brands avoids expected frequencies less than 5,  so 
with EDSS of 1, 2 and 4,this test is reliable. 
 
The duration of disease in the total of the population 
was from 7 days to 12 years. The mean duration of 
disease was 1429.66 days (4 years).  The scores of 
the EDSS ranged from 2 to 6 with a mean ± SE of 2.3 
± 0.18. Most patients had a RRMS course of the 
disease, 25(52.08%), while 13(27.08%) had a 
secondary progressive (SPMS) course and 
10(20.83%) had a CIS course of the disease. 
The blood Pb level in MS patients  
The most Pb level measured in the blood samples of 
patients was <20 μg/l (70.83% of the total 
population). 10.42% samples had the Pb level of 20-
70μg/l, 6.25% were within the level of 70-100μg/l 
and 12.50% covered the level of 100-130μg/l. 
Generally, regarding the patient characteristic, there 
were no statistically significant differences between 
men and women except for the variable of disease 
duration. As showed in table 1, the duration of 
disease of 4 years was mostly observed in the men. In 
addition, the duration of disease in 8-12 years was 
only observed in females. EDSS of 2 in women 
(46.88%) and in men (81.25%) was the highest. 
EDSS of 4 (25.00%) was identified only in women.  
The relationship between the blood Pb level in 
MS patients and their clinical data 
Table 2 also shows the relationship between blood Pb 
levels and the clinical data in the total population. To 
avoid the unreliability of the chi-squared test (due to 
frequency below 5), we had to merge some 
subgroups. No significant differences were noted in 
the levels of Pb in blood in the case of all variables 
except for EDSS (P<0.05).  The blood samples with 
thePb level of <20 μg/l had the highest frequencies in 
EDSS score of 1(20.59%), 2(47.06%) and 4(32.35%), 
so it could  be justified that most patients (70%) had 
the blood Pb level of <20 μg/l.  
In spite of merging some data in the group of disease 
duration, the chi-square test was unreliable, so the 
relationship between Pb level (with the concentration 
of more than >20 μg/l) and disease duration was 
investigated by analysis of variance (ANOVA). It 
was found that disease duration was positively 
correlated (p=0.073, R-Sq = 66.23%) with blood Pb 
concentration (Fig. 1).  
Table 2 : The relationship between blood Pb levels and 
their clinical data in total population 
Pb ( g/l)* 
Variables 
100-130 20-100 <20 
  
 
Age of subjects 
(year) 
7(20.59) 12(35.29) 15(44.12) 20-30 
2(25.00) 3(37.50) 3(37.50) 30-40 
0(0.00) 3(50.00) 3(50.00) >40 
   Residence 
1(16.67) 1(12.50) 11(32.35) Rural 






3(50.00) 2(25.00) 7(20.59) 1 
3(50.00) 6(75.00) 16(47.06) 2 
0(0.00) 0(0.00) 11(32.35) 4 
   Clinical diagnosis 
5(83.33) 4(50.00) 16(47.06) RRMS 
0(0.00) 1(12.50) 12(35.29) SPMS 
1(16.67) 3(37.50) 6(17.65) CIS 
- Figures in parentheses indicate percentages 
*No significant differences were noted between males and females 
for all variables in chi-square test (P>0.05), except for Expanded 
Disability Status Scale (EDSS) (P<0.05). 
a Likelihood Ratio Chi-Square = 9.912, P-Value = 0.042 
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Fig. 1: The relationship between the blood Pb level of MS 
patients (>20 g/l) and their disease duration  
 
DISCUSSION  
The primary purpose of this study was to evaluate the 
role of lead as a risk factor in damaging the immune 
system and probably, influencing the development of 
MS. So the study of the clinical features of MS such 
as gender, age, residence, disease duration, disability 
degree, and clinical diagnosis could clarify existence 
or non existence a relationship between of the 
increase of the blood lead level and the development 
of neurologic disorders. The main finding of this 
study showed that the highest rate of MS was in 
women. The survey of the Multiple Sclerosis 
International Federation (MSIF) also found that the 
median estimated female: male ratio was 2.0 
worldwide [5]. In studies conducted by Gregory II et 
al. in the United States and Pugliatti et al. in Europe, 
the women to men ratio were 3.20 and around 2, 
respectively [1,20]. The females were more likely to 
self-report being diagnosed with MS thus; there were 
a large number of cases among females [20]. In 
addition, MS rate (60%) was the highest among cases 
who were 25- 40 years old. The findings of other 
researches agreed with these results [5, 21]. 
Relapsing-remitting MS (RRMS) was the most 
common disease course in patients (52%).  From the 
geographic distribution of MS, we observed the 
highest total MS prevalence rates were among urban 
residents. This distribution was according to 
resident’s distribution in Isfahan province. However, 
no statistical difference was found between the Pb 
level of subjects living in rural and urban areas 
because the populations were selected in central and 
suburban areas of Isfahan to assess the average 
exposure and exclude any specific source of the 
pollutant. The main sources of Pb exposure for the 
non-exposed general population are food, water and 
airborne particulate (smoke included) [16].  
Also, previous researchers reported that Pb was 
significantly accumulated with increasing age [16, 
21-23]. However, in our study, no significant 
difference was observed at the level of Pb among age 
groups,  but there was a significant correlation 
between the blood Pb level and disease 
duration(p<0.05). In fact, with the increase of  MS 
patients disease duration, their blood Pb level (>20 
μg/l) was increased too. It can be explained by the 
accumulation and binding of Pb to bone during time 
[16, 23] as Pb was used as a faulty building block in 
place of calcium; then we would expect blood lead 
levels to increase by passing time [24]. These results 
implied that disease duration was an important factor 
in increasing the accumulation of Pb. 
In this study, the mean of the blood levels of lead in 
70% of MS patients was <20 μg/ l and  in others, it 
was 85.13μg/ l. Table 3 presents a brief literature 
review on  the blood level of lead in neurological 
disorders such as motor neuron disease (MND) and 
multiple sclerosis [8, 11, 25-28]. 
When compared with the reference values, the mean 
Pb concentration in our study was <20 μg/l in 70% of 
MS patients and only 12.5% of patients had Pb level 
of 100-130 μg/l. These findings conformed to those 
obtained by other researchers, as shown in table 3. 
The difference in Pb levels in these studies was 
related to the area condition, different population 
groups and measurement method, among other 
things. Some reports have indicated that neurological 
impacts of lead occur at a level of 20- 50 μg/l in 
children and 180 μg/l in adults [29]. However, the 
lead concentration obtained from our study was 
lower. Also, the lead concentration in our study was 
in the range obtained by Talebi and Malekiha (2009) 
[17]. Their study was on heavy metals levels in 
whole blood samples  obtained from those residents 
of Isfahan city who had referred to the Isfahan Blood 
Transfusion Organization during 2006-2007 (300 
healthy adult people) and the mean concentrations of 
lead measured in the blood of the Isfahan residents 
was 150 μg/l by an atomic absorption spectrometer 
equipped with a GTA-110 graphite system. This 
confirmed our findings, showing that there was no 
significant difference in Pb level among the normal 
population and MS patients in Isfahan city. Also, the 
mean Pb concentration in most MS patients in our 
study was lower than the current threshold for Pb 
toxicity – as adopted by the US Centers for Disease 
Control and Prevention (CDC) since 1991 and by the 
World Health Organization since 1995 – is defined as 
the blood Pb level of <100μg/l [30,31].   
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Table 3 : Literature review on the blood level of lead in neurological disorders (µg/l) 
 
However, one the most important reason for the 
relatively high level of Pb in blood sample of Isfahan 
people was that the high concentrations of Pb in the 
air of Isfahan closely were correlated with the high 
concentrations of these metals in soil such that the 
average concentration of Pb in the soils of Isfahan 
was 37.4 (17- 107) mg/kg dry soil in 2006 [32] and 
297 mg/kg in 2008-2010 [33], which was less than 
the United States Environmental Protection Agency 
(US EPA) guideline (400 mg/kg) [34] and in range of 
Iran soil standard in pH>7 like alkaline soil of 
Isfahan (75-300 mg/kg) [35].  Also, the average 
concentration of Pb in the air of Isfahan was 297.5 
ng/m3 [32], is less than that of the World Health 
Organization (WHO) (500 ng/m3) [36] and more 
than US EPA guideline (150 ng/m3) [37]. The 
widespread presence of pollution sources  in Isfahan, 
such as the Irankouh lead and zinc mine located in 
the southwest of Isfahan (Pb level of 101.87mg/kg) 
[38], Isfahan Mobarakeh Steel Company and Isfahan 
Steel Company (Pb concentration of 1.3 to 4.85 
mg/kg in 2001), agriculture run off, and automobiles, 
yields a vast amount of the contaminant materials, 
especially Pb[32,39-40].  
However, while there are a potential risk as a result 
of the levels of Pb exposure and the possible effects 
on neurodevelopment [16,27], in our study no 
statistically significant difference was found between 
the Pb level of subjects and some patient 
characteristics including age, gender, residence, 
clinical diagnosis. So these findings did not provide 
evidence to support the hypothesis that lead may 
cause the MS disease, although its limited size 
prevents the generalization of the results.  
Turabelidze et al., McGrother et al. and Birmingham 
Research Unit of the Royal College of General 
Practitioners (RCGP–BRU), in their studies on  
multiple sclerosis prevalence and possible Pb 
exposure, did not confirm the possibility that 
abnormal tissue lead levels would be related to 
multiple sclerosis in the patients. [8,41,26] However, 
in some areas, an unusually high prevalence of 
neurodegenerative diseases such as MS and MND 
was found to be associated with high levels of Pb[27, 
42, 28]. In addition, in the study by Fort et al. a 
significant reduction in blood mean concentration of 
the Pb level in MS patients was observed [11].  
However, we cannot ignore the possibility that a 
short exposure to a large amount of lead during the 
development of the nervous system might interfere 
with myelin synthesis such that it may, in turn, start a 
series of irreversible changes which, in time, produce 
the symptoms of multiple sclerosis. In fact, the 
etiological significance of this relationship is not 
clear, but it is proven that there are the significant 
relationship between the high level of lead and 
incidence of it, both singly or synergistically with 




Multiple sclerosis (MS) 










  N.A.A. - 
c England 21 AAS 
187 
(108-266) 
d Italy 60 ICP-MS 
24.3  
(11.6-37) 
Motor neuron disease 
(MND) 
e Italy 15 GFAAS 
127.1  
(59.3-194.9) 
f Germany 9 E. A. A. S 
86.5 
(47.4-125.6) 
a Data from McGrother et al.,1999 [8], b Ward et al.,1979 [25] , c  RCGP–BRU,1976[26], d Forte et al., 2005[11],    e 
Vinceti et al., 1997 [27], f Stober et al., 1983[28]. 
 -Not reported/or determined 
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other trace element, the same progress is being 
concerning to other elements [26].  
 
CONCULUSIONS  
The mean concentration of lead in 70% of  the blood 
sample used in our study population was lower than 
20 μg/l and only about 12% patients had Pb level of 
100-130 μg/l. We found no direct evidence for lead 
intoxication as a cause of MS using the relationship 
between the blood lead level and the clinical features 
of MS patients but its limited size did not allow us to 
generalize our results. However, the exposure to 
heavy metals such as Pb is a potential candidate 
because of the proven neurotoxicity, but it is still not 
well known if the lead exposure can affect human 
health risk for the development of MS. The clinical 
and demographic characteristics in our study were 
similar to those in other reports. Therefore, more 
accurate studies with larger samples are required to 
further support these results. Also, the findings of this 
report highlighted the need for other studies that can 
identify the major reasons at high risk for MS.   
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